TL;DR
This paper introduces a new human reference serum, 007sp, to replace the dwindling supply of the established standard, 89SF. This new serum is crucial for maintaining consistency in pneumococcal antibody testing, particularly for evaluating new vaccines and ensuring comparability to previous efficacy studies.
What Problem Does This Paper Address?
The paper addresses a critical supply issue for a vital scientific tool: the reference standard serum (lot 89SF) used in enzyme-linked immunosorbent assays (ELISAs) for measuring antibodies against Streptococcus pneumoniae. This standard has been in use since 1990 and was instrumental in the evaluation of the first pneumococcal conjugate vaccine (PCV7). With only a few years' supply remaining, there was a pressing need for a replacement to avoid severing the link to past clinical efficacy data. This is particularly important because a common licensure strategy for new pneumococcal vaccines involves demonstrating immune responses comparable to those seen with PCV7. Without a consistent reference standard, this comparability would be lost.
Methods
The researchers established the new reference serum, 007sp, by immunizing 278 volunteers with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax II). Blood samples were collected twice within 120 days post-vaccination. The plasma was then pooled, tested for infectious agents (HBV, HCV, HIV), and lyophilized into 15,333 vials.
The core of the method involved "immunological bridging" of 007sp to the existing 89SF standard. This was achieved by having five independent laboratories perform ELISAs to establish equivalent reference values for 13 pneumococcal serotypes. They used the World Health Organization (WHO) reference ELISA protocol. To further validate 007sp, they also reassigned concentrations for 12 existing WHO calibration sera using 007sp as the new reference and compared these to values derived using 89SF. Statistical analysis, including linear mixed-effects analysis of variance (ANOVA) and concordance correlation coefficients (CCC), was used to assess agreement and precision among the laboratories.
Datasets
The primary "dataset" in this study is the newly created reference serum, 007sp, derived from the pooled plasma of 278 vaccinated volunteers. Additionally, the study utilized a panel of 12 existing WHO calibration sera. The established reference serum, lot 89SF, served as the benchmark against which 007sp was validated.
Key Insights and Ideas
- The Importance of Continuity in Reference Standards: This paper underscores how critical it is to have stable, long-term reference standards in serological assays. The depletion of 89SF threatened to break a crucial chain of evidence linking vaccine efficacy to antibody levels.
- Bridging is Key: The "immunological bridging" approach, where the new standard is directly compared to the old one across multiple labs, is a robust method for establishing equivalence.
- Multi-laboratory Validation is Essential: Using five independent laboratories to perform the bridging assays significantly increases confidence in the assigned values for 007sp.
- The Need for Double Adsorption: The new protocol for 007sp involves double adsorption (using cell wall polysaccharide and serotype 22F polysaccharide) to remove cross-reactive antibodies. This is an improvement over the single adsorption used for 89SF, leading to more specific antibody measurements.
Key Results
- Successful Establishment of 007sp: The study successfully established 007sp as the new human pneumococcal reference standard serum.
- High Agreement: Excellent agreement was observed between the antibody concentrations determined using 007sp and those determined using 89SF across multiple laboratories and serotypes. Concordance correlation coefficients (CCC) were consistently high (often exceeding 0.97).
- Sufficient Supply: 007sp was prepared in a large quantity (15,333 vials), ensuring its availability for at least 25 years with judicious use.
- Validation of WHO Calibration Sera: The reassignment of values for 12 existing WHO calibration sera using 007sp also showed excellent agreement, further validating the new standard.
Limitations and Future Work
- Potential for Lab-Specific Deviations: While overall agreement was high, the paper notes that one laboratory (lab 3) showed some deviations, particularly for serotype 14, which was attributed to a single outlier value. This highlights the ongoing need for rigorous quality control in multi-laboratory studies.
- Future OPA Studies: The authors mention that the new reference sera will also be valuable for functional assays like opsonophagocytosis assays (OPA). A multilaboratory OPA study is planned to assign OPA titers for these sera, expanding their utility beyond ELISA.
- Broader Serotype Coverage: The paper focuses on 13 serotypes for the initial assignment. The authors indicate that assignments for an additional 11 serotypes contained in the 23-valent vaccine will be undertaken in the future, further enhancing the comprehensive nature of the new standard.
Summary updated